Tremor – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Tremor – Drugs In Development, 2024 report and make more profitable business decisions.
Tremor is a neurological condition characterized by involuntary shaking or trembling movements in various body parts, primarily the hands but potentially affecting the arms, legs, head, vocal cords, and trunk, as a result of uncontrollable muscle contractions. Its impact varies, causing intermittent or constant challenges in daily tasks like writing, typing, eating, and dressing. While not life-threatening, severe cases can lead to disabilities. Essential tremor, Parkinsonian tremor associated with Parkinson’s disease, and dystonic tremor are common types. The cause often stems from deep brain issues, with some types being hereditary. Various factors, including neurologic disorders, certain medications, alcohol use disorder, poisoning, hyperthyroidism, and anxiety, may contribute. Symptoms range from rhythmic shaking to difficulty writing. Diagnosis involves a neurological exam assessing balance, speech, and muscle stiffness. Treatment options encompass medications, Botox injections, surgery (such as deep brain stimulation), and therapy to manage tremor and its daily implications.
The Tremor drugs in development market research report provide comprehensive information on the therapeutics under development for Tremor, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Tremor and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Tremor | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 21 molecules, with 20 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Tremor therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Tremor pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Tremor treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AbbVie IncAfaSci Inc
Bod Science Ltd
ES Therapeutics LLC
GABA Therapeutics Inc
Gerbera Therapeutics Ltd
Jazz Pharmaceuticals Plc
Merz Pharma GmbH & Co KgaA
Neurocrine Biosciences Inc
Nissan Chemical Corp
Novartis AG
OB Pharmaceuticals
Praxis Precision Medicines Inc
Puretech Health Plc
Sage Therapeutics Inc
University of California San Diego
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Tremor reports